Covilife MBD 275: Ingredients, Uses, How It Works and Complete Safety Guide 2026
Covilife MBD 275 is a fixed-dose combination antiparasitic tablet manufactured in India containing two active ingredients in a single tablet: ivermectin 25mg and mebendazole 250mg. The "275" in the product name represents the combined total milligrams — 25mg of ivermectin plus 250mg of mebendazole. It is produced by Kachhela Medex and distributed through pharmaceutical export channels as a combination anthelmintic (anti-worm) treatment for complex or resistant parasitic infections.
Understanding Covilife MBD 275 requires understanding both its individual active ingredients — which are among the most widely researched antiparasitic compounds in modern medicine — and the clinical rationale for combining them in a single formulation. Ivermectin targets a completely different mechanism from mebendazole, meaning the two drugs attack parasitic infections through non-overlapping pathways simultaneously. This dual-mechanism approach is the same rational strategy used in combination antibiotic therapy for resistant bacteria and in combination chemotherapy for cancer — making it harder for parasites to survive or develop resistance to treatment.
In 2026, both ivermectin and mebendazole are also at the centre of significant scientific research interest beyond their established antiparasitic roles — particularly in oncology, where both compounds have demonstrated anti-tumour mechanisms in preclinical and early clinical research. This broader context makes understanding the pharmacology of each component particularly relevant for patients and researchers.
This complete 2026 guide covers the exact composition and naming convention of Covilife MBD 275, how each active ingredient works at the molecular level, why combining them produces synergistic antiparasitic activity, the specific parasitic conditions this combination addresses, dosage and administration guidance, the safety profile of each component, important drug interactions, who should not use this combination, and the current research context for both drugs.
TheMedicineKart stocks the individual components of Covilife MBD 275 separately allowing patients to access each active ingredient under the guidance of their healthcare provider:
Ivermectin 12mg tablets: [Ivermectin 12mg Tablets]
Mebendazole 100mg tablets: [Mebendazole 100mg Tablets]
Mebendazole 500mg tablets: [Mebendazole 500mg Tablets]
Composition — What Is in Covilife MBD 275
Covilife MBD 275 contains exactly two active pharmaceutical ingredients per tablet:
Ivermectin: 25mg per tablet
Mebendazole: 250mg per tablet
Combined total: 275mg (the source of the "275" product designation)
Drug class: fixed-dose combination anthelmintic / antiparasitic
Manufacturer: Kachhela Medex (India)
How the name breaks down:
"Covilife" — the product brand family used by the manufacturer for several antiparasitic formulations (Covilife 12 = ivermectin 12mg; Covilife 40 = ivermectin 40mg)
"MBD" — abbreviation for mebendazole, the second active ingredient
"275" — the combined milligram strength of both active ingredients (25 + 250 = 275)
Available format: oral tablet, for oral administration
Note on dosage strength: 25mg ivermectin is a substantially higher dose than standard individual ivermectin products. Standard ivermectin tablets are typically 3mg, 6mg, 12mg, or 15mg for antiparasitic treatment. The 25mg dose in Covilife MBD 275 is calculated for use in patients where weight-based dosing — typically 0.2–0.4 mg/kg — requires higher total doses (for example, a patient weighing 75–125kg at the 0.2mg/kg dose). It is also used in some off-label protocols. This high-dose ivermectin formulation is not FDA-approved in the USA and is an Indian-manufactured export product.
How Each Active Ingredient Works
Understanding Covilife MBD 275's activity requires understanding both components separately — because they work through entirely different and complementary mechanisms:
Ivermectin 25mg — Mechanism 1: glutamate-gated chloride channel binding:
Ivermectin selectively binds to and potentiates glutamate-gated chloride channels (GluCls) in the nerve and muscle cells of invertebrates — nematodes, insects, and ectoparasites. These channels are found in parasites but not in mammals (which have GABA-gated, not glutamate-gated, chloride channels). Ivermectin binding causes:
Increased chloride ion permeability across the parasite cell membrane
Hyperpolarisation of the membrane — the cell cannot fire action potentials
Paralysis and death of the parasite
In nematodes: the drug also affects pharyngeal pumping and reproduction — reducing egg output even at sub-lethal concentrations
Ivermectin spectrum — what it treats:
Strongyloides stercoralis (threadworm/strongyloidiasis) — FDA-approved first-line treatment
Onchocerca volvulus (river blindness / onchocerciasis) — FDA-approved
Scabies (Sarcoptes scabiei) — widely used first-line treatment
Head lice (Pediculus capitis) — FDA-approved oral (weight ≥15kg)
Lymphatic filariasis — used in mass drug administration programmes worldwide
Cutaneous larva migrans, gnathostomiasis — off-label but effective
Mebendazole 250mg — Mechanism 2: tubulin polymerisation inhibition:
Mebendazole works through a completely different pathway — it belongs to the benzimidazole class and works by binding to the β-tubulin subunit of parasitic cells, preventing tubulin polymerisation — the process by which microtubules are assembled. Without functional microtubules, parasites cannot:
Divide (mitosis requires microtubule spindle formation)
Maintain cell structure (cytoskeleton depends on microtubules)
Absorb glucose (disruption of secretory microtubules in the absorptive surface)
Produce eggs (reproduction requires microtubule-dependent processes)
The net result: mebendazole causes progressive glucose depletion, cell death, and reproductive failure in susceptible worms. It is effective against both adult worms and eggs of many species.
Mebendazole spectrum — what it treats:
Ascaris lumbricoides (roundworm) — highly effective
Trichuris trichiura (whipworm) — moderately effective; combination with ivermectin significantly improves cure rates
Ancylostoma duodenale and Necator americanus (hookworm) — effective
Enterobius vermicularis (pinworm) — highly effective
Taenia species (tapeworm) — partial activity
Echinococcus (hydatid disease) — long-term high-dose use
Why combining these two mechanisms is clinically rational:
The dual-mechanism combination is particularly valuable for:
1. Trichuris trichiura (whipworm) treatment: mebendazole alone has a relatively low single-dose cure rate for T. trichiura (approximately 30–50%). A pivotal randomised controlled trial (NCT01050452, completed) demonstrated that mebendazole + ivermectin together produces significantly higher cure rates than either drug alone for T. trichiura — the most difficult common soil-transmitted helminth to treat.
2. Mixed parasitic infections: in endemic regions and in patients who may carry multiple co-existing helminth species, a combination covering both nematocidal mechanisms ensures broader coverage in a single tablet
3. Reducing resistance risk: as with antibiotic combinations, using two drugs with non-overlapping mechanisms reduces the probability that individual parasites can survive through resistance to both simultaneously
Clinical Uses of the Combination
Covilife MBD 275 is used primarily for:
Treatment of soil-transmitted helminthiases (STH) — complex or refractory cases:
Soil-transmitted helminths — Ascaris, Trichuris, hookworm, Strongyloides — are among the most prevalent parasitic infections globally, including in populations with suboptimal sanitation. Standard single-drug treatment (albendazole 400mg single dose or mebendazole 500mg single dose) is highly effective for Ascaris and hookworm but has limitations for T. trichiura and S. stercoralis. Combining mebendazole with ivermectin addresses both of these harder-to-treat species simultaneously.
Strongyloides stercoralis (threadworm) with concurrent STH co-infection:
Strongyloides is unique among helminths in its ability to auto-infect — the parasite's larvae can re-infect the same host without external re-exposure, allowing chronic infection to persist for decades. In immunosuppressed patients (on corticosteroids, chemotherapy, or with HIV), Strongyloides can cause life-threatening hyperinfection syndrome. Ivermectin is the treatment of choice for Strongyloides; mebendazole addresses any co-existing intestinal nematode burden simultaneously.
Mixed ectoparasite and endoparasite presentations:
In patients with concurrent intestinal worm burden and ectoparasite infestation (scabies, head lice), the ivermectin component addresses the ectoparasite while mebendazole addresses intestinal helminths.
Research context — off-label use in cancer protocols:
Both ivermectin and mebendazole are currently under investigation as potential anti-cancer agents (see our dedicated guides for the full evidence). Patients using both drugs as part of cancer adjunct protocols sometimes seek fixed-dose combination products. The research rationale for combining them in oncology mirrors the antiparasitic rationale — non-overlapping mechanisms creating complementary anti-tumour activity.
Dosage and Administration
Important preliminary note: Covilife MBD 275 contains 25mg ivermectin per tablet high dose that should only be used when a healthcare provider has calculated that this dose is appropriate for the patient's body weight and clinical indication. The standard ivermectin dosing formula is 0.2–0.4 mg/kg body weight. At 25mg per tablet, this formulation is appropriate for adults weighing approximately 65–125kg depending on the dose required.
General dosing guidance:
Take orally with a full glass of water
Take on an empty stomach (ivermectin component is optimally absorbed with some fat — however, standard antiparasitic dosing typically uses fasting; discuss timing with your prescriber)
Swallow tablets whole — do not crush or chew
Dosing frequency and duration depend on the specific parasitic indication and are determined by the prescribing physician
A follow-up stool examination at 2–4 weeks post-treatment is recommended to confirm eradication
Factors requiring dose adjustment or caution:
Low body weight (below 50kg): 25mg ivermectin may exceed recommended weight-based dose; use individual component tablets at appropriate doses instead
Renal impairment: mebendazole is minimally absorbed systemically — no dose adjustment needed; ivermectin: caution in severe renal failure
Hepatic impairment: both drugs are hepatically processed; use with caution in significant liver disease; monitor liver function
Elderly patients: increased sensitivity to ivermectin CNS effects; start conservatively
Safety Profile — Both Active Ingredients
Ivermectin 25mg component:
Common side effects (Mazzotti-like reaction — die-off reaction):
When ivermectin kills large numbers of parasites rapidly, a Mazzotti reaction can occur — the immune system responding to dying parasite antigens:
Fever and chills
Headache
Myalgia (muscle aches)
Pruritus (itching) — from dying parasite release
Dizziness and lightheadedness
Nausea and diarrhoea
These reactions are typically self-limiting and resolve within 24–48 hours. They are more pronounced when the initial worm burden is heavy.
Neurological effects — the most important safety concern:
At higher ivermectin doses, CNS effects can occur — particularly in vulnerable populations:
Somnolence, confusion, ataxia (unsteady gait)
Elevated risk in patients with disrupted blood-brain barrier (meningitis, HIV CNS disease)
Elevated risk in patients with Loa loa co-infection — high microfilarial loads can cause severe encephalopathy with ivermectin (primarily relevant in Sub-Saharan Africa endemic areas)
Drug interactions that inhibit P-glycoprotein (cyclosporine, certain HIV drugs) increase ivermectin CNS penetration
Mebendazole 250mg component:
Safety advantage — very low systemic absorption:
A critical safety feature of mebendazole is its extremely low oral bioavailability — approximately 1–10% of an oral dose is absorbed systemically. The vast majority remains in the gut where it acts locally against intestinal parasites. This makes systemic side effects uncommon at standard doses:
Transient abdominal pain and diarrhoea — most common; mild
Nausea — mild
Flatulence
With long-term high-dose use (for hydatid disease — not standard antiparasitic use):
Liver enzyme elevation — monitor LFTs with extended courses
Bone marrow suppression (neutropenia, thrombocytopenia) — rare; with prolonged high-dose use only
Hair loss — with very prolonged use
Contraindications — who should NOT use Covilife MBD 275:
Pregnancy: ivermectin is generally avoided in the first trimester; mebendazole is contraindicated in the first trimester (Category C — teratogenic in animal studies); discuss risk-benefit with prescriber for second/third trimester
Breastfeeding: ivermectin passes into breast milk in small amounts — delay breastfeeding 1 week after high-dose use; mebendazole minimally absorbed generally considered safe during breastfeeding
Known hypersensitivity to ivermectin or mebendazole or benzimidazole class drugs
Children under 15kg body weight (ivermectin safety not established below this threshold for the oral route)
Severe hepatic (liver) impairment
Loa loa co-infection with high microfilarial counts — severe encephalopathy risk with ivermectin
Drug Interactions
Interacting Drug | Drug Affected | Risk | Action |
Warfarin (anticoagulant) | INR may be raised by ivermectin + mebendazole | Moderate — bleeding risk | Monitor INR carefully; may need warfarin dose reduction |
Cyclosporine | Ivermectin blood levels raised (P-glycoprotein inhibition) | Moderate — CNS toxicity risk | Avoid concurrent use or monitor carefully |
Levamisole | Raises ivermectin blood levels | Moderate | Monitor for ivermectin toxicity |
Ritonavir and HIV protease inhibitors | Raise ivermectin levels via CYP3A4 and P-gp inhibition | Moderate | Monitor for enhanced ivermectin effects |
Metronidazole | Additive hepatotoxicity with long-term mebendazole | Mild | Monitor liver function with prolonged concurrent use |
Alcohol | Increased CNS depression with ivermectin component | Mild | Avoid alcohol during and 24 hours after ivermectin dosing |
Cimetidine (H2 blocker) | Increases mebendazole plasma levels | Mild | Clinically minimal at standard antiparasitic doses |
Covilife MBD 275 vs Individual Components — When to Use Each
Option | Ivermectin Dose | Mebendazole Dose | Best For |
Covilife MBD 275 | 25mg | 250mg | Adults ≥65kg needing dual antiparasitic coverage (T. trichiura + Strongyloides; mixed infection); cancer adjunct protocols using both compounds |
Ivermectin 12mg alone | 12mg | None | Standard adult antiparasitic dose (60kg patient at 0.2mg/kg); scabies; head lice; single-drug antiparasitic indication |
Mebendazole 100mg alone | None | 100mg | Pinworm (single dose treatment); mild intestinal roundworm in children |
Mebendazole 500mg alone | None | 500mg | Single-dose treatment for Ascaris, hookworm, Trichuris (though lower cure rates for Trichuris) |
Ivermectin 12mg + Mebendazole 500mg separately | 12mg (two tablets = 24mg) | 500mg | Flexible dosing when body weight requires specific ivermectin dose calculation; allows dose individualisation not possible with fixed combination |
For our complete guide on oral ivermectin — FDA-approved uses, standard dosing, and full evidence for every antiparasitic indication: [Ivermectin for Humans: FDA-Approved Uses, Strengths and Dosage Guide]
For our deep-dive guide on fenbendazole and the broader antiparasitic cancer research landscape — the growing scientific and public interest in benzimidazole compounds: [Fenbendazole Absorption, Supplement Protocol and Cancer-Type Evidence]
For our guide on the combined ivermectin and fenbendazole cancer research — the most current 2026 evidence including NCI investigation and City of Hope trial: [Ivermectin and Fenbendazole for Cancer: What the 2026 Science Actually Shows]
NIH ClinicalTrials.gov provides the registered trial data on ivermectin + mebendazole combination for Trichuris trichiura at: https://clinicaltrials.gov/study/NCT01050452
NIH StatPearls provides the clinical review of ivermectin at: https://www.ncbi.nlm.nih.gov/books/NBK493217/
MedlinePlus provides comprehensive patient information on mebendazole at: https://medlineplus.gov/druginfo/meds/a682315.html
Frequently Asked Questions
What is Covilife MBD 275 and what does it contain?
Covilife MBD 275 is a fixed-dose combination antiparasitic tablet manufactured by Kachhela Medex in India. Each tablet contains ivermectin 25mg and mebendazole 250mg — the "275" in the product name reflects the combined total milligrams of both active ingredients. It is a combination anthelmintic designed to treat complex or mixed parasitic infections by attacking parasites through two completely different and complementary mechanisms simultaneously — ivermectin through glutamate-gated chloride channel paralysis, and mebendazole through tubulin polymerisation inhibition.
Why combine ivermectin and mebendazole in a single tablet?
The two drugs have non-overlapping mechanisms of action — ivermectin paralyses parasites through chloride channel disruption while mebendazole prevents cell division and glucose absorption by blocking tubulin assembly. Combining them provides broader spectrum coverage (treating species that respond well to one drug but less to the other), higher cure rates for difficult species like Trichuris trichiura (confirmed in an RCT, ClinicalTrials.gov NCT01050452), and reduced likelihood of parasitic resistance — the same rationale used in combination antibiotic and combination chemotherapy strategies.
Is Covilife MBD 275 FDA-approved?
Covilife MBD 275 is an Indian-manufactured product not FDA-approved in the United States. Neither the 25mg ivermectin dose nor the fixed-dose combination with mebendazole has received FDA approval. The individual active ingredients — ivermectin and mebendazole — are both available in FDA-approved formulations in the US, but at different strengths and not as a fixed combination. Patients seeking either drug should use them under the guidance of a licensed US healthcare provider with individually dosed FDA-approved formulations.
What are the side effects of Covilife MBD 275?
The side effects come primarily from the ivermectin component — mebendazole is very poorly absorbed systemically and has minimal systemic effects at standard antiparasitic doses. Ivermectin can cause a Mazzotti-like die-off reaction when killing large numbers of parasites: fever, headache, muscle aches, itching, dizziness, and nausea — typically resolving within 24 to 48 hours. More serious neurological effects (drowsiness, confusion, unsteady gait) can occur at higher doses or in patients on drugs that increase ivermectin CNS penetration (cyclosporine, certain HIV drugs). Warfarin users should monitor INR carefully as both drugs can affect anticoagulation.
Who should not take Covilife MBD 275?
It should not be used in: patients with known hypersensitivity to ivermectin, mebendazole, or benzimidazole class drugs; children under 15kg body weight; the first trimester of pregnancy (both components have teratogenic concerns at high doses); patients with Loa loa co-infection and high microfilarial counts (risk of severe ivermectin-induced encephalopathy); patients on cyclosporine without close monitoring; patients with severe hepatic impairment. Always disclose all current medications to your healthcare provider before using this combination.
Comments